Here is a roundup of Wednesday’s most significant analyst ratings calls.
UBS initiated CoreWeave with a Buy rating and a $120 price target, implying roughly 40% upside from the current price. The firm said CoreWeave offers strong growth potential as UBS expands its coverage of the AI infrastructure market beyond hyperscalers and Oracle.
KeyBanc initiated Guardian Pharmacy Services at Overweight, calling the company “best-in-class.” KeyBanc said Guardian has spent the past 20 years building a leading long-term-care pharmacy business focused on assisted-living facilities.
Wolfe reiterated its Outperform rating on Amazon and raised its price target to $320 from $315. The firm said its estimates for AWS revenue and operating income are 8.5% and 3.9% above the street, respectively. Wolfe also highlighted Amazon’s underappreciated core AWS margins, updated its Bedrock revenue and margin framework, and revised its projections for Anthropic and OpenAI-related contributions.
BMO initiated HCA Healthcare at Outperform, citing the healthcare company’s resilience. The firm said investments in attractive geographies with favorable demographic trends, combined with benefits from HCA’s resiliency program, should support EBITDA growth in line with its longer-term 4% to 6% target CAGR despite the challenging macroeconomic environment.
Morgan Stanley reiterated its Overweight rating on SpaceX and said the company is not currently a likely threat to major wireless carriers. The firm expects SpaceX to have limited access to significant amounts of critical mid-band spectrum in urban areas, potentially delaying any mobile virtual network agreement with the industry’s largest carriers for several years.
Wells Fargo initiated Beta Bionics at Overweight with a $28 price target. The firm highlighted the company’s differentiated Mint algorithm and its position in the fast-growing patch-pump market, projecting revenue growth of approximately 38% annually through 2030, supported by pharmacy, type 2 diabetes and pipeline tailwinds.
Oppenheimer initiated Teva Pharmaceuticals at Outperform with a $50 price target, citing growth potential in the pharmaceutical business.
Bernstein initiated coverage of Amphenol and TE Connectivity at Outperform, saying the interconnect companies have substantial room for growth.
Rosenblatt reiterated its Buy rating on Palantir and remained bullish on the Federal Aviation Administration’s use of the company’s aircraft-safety monitoring solution. Rosenblatt said the FAA’s Monday rollout of its SMART, or Strategic Management of Airspace, Routes, and Trajectories, system demonstrates the opportunity for Palantir. The AI-powered tool began managing flights for three major Washington-area airports.
UBS initiated Buy ratings on five AI-focused data-center and bitcoin-mining stocks: WULF, HUT, APLD, CORZ and CIFR. The firm said the companies are positioned for rapid growth as AI adoption accelerates and developers’ ability to meet demand remains constrained.
Seaport initiated Marvell at Buy, saying the company has a long runway for growth as its interconnect and custom-silicon businesses benefit from strong demand for AI infrastructure.
Stifel upgraded Microsoft to Buy from Hold, saying the technology company has clearly improved since its June quarterly results. Stifel expects sustained Azure upside of 200 to 300 basis points, driven by incremental capacity monetization, reduced LLM research and development intensity and accelerating OpenAI-related revenue contributions.
Citi reiterated its Buy rating on Micron and raised its price target to $1,300 from $1,150 ahead of the company’s earnings report next week. The firm adjusted its target using a consistent 8 times price-to-earnings multiple applied to revised 2027 earnings per share.
Bank of America reiterated its Buy rating on Apple after its checks indicated that iPhone order lead times remained stable. The firm said ship dates listed on Apple’s website and carrier sites as of September 21 were roughly consistent with last year’s preorder cycle for the iPhone 18 Pro and Pro Max models.
JPMorgan upgraded BP to Overweight from Neutral, describing the company as being on a “road to redemption.” The firm said macro tailwinds and company-specific renewal create an opportunity to reduce macroeconomic cyclicality and strengthen BP’s fundamentals through 2028.
JPMorgan upgraded Graphic Packaging to Overweight from Neutral, citing an attractive return profile. The shares trade below 10 times 2027 earnings and offer a dividend yield of approximately 5%, although the firm lowered its December 2027 target price to $11.50 from $12.50.
Citi initiated Madrigal Pharmaceuticals at Buy/HR with a $725 price target, calling the biotech company compelling and undervalued.
Compass Point initiated FS Specialty Lending Fund at Buy.
Citi initiated Maze Therapeutics at Buy/HR with a 12-month price target of $50, citing several positive catalysts ahead for the biotech company.
Needham initiated Belden at Buy with a $140 price target, identifying the industrial technology company as a beneficiary of reshoring.
Oppenheimer initiated The Toro Company at Outperform with a $120 price target, calling the lawn-maintenance company’s shares compelling.
